Molecular genetics in childhood hypertension

Progress in Pediatric Cardiology

Volumn 9, Issue 3, 1998, Pages 203-212

  Morris, Brian J ^a  

^a Dept Physiol Inst Biomed R ^*  (Australia)

Author keywords

Apparent mineralocorticoid excess; Glucocorticoid remediable aldosteronism; Liddle's syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ALDOSTERONE SYNTHASE; AMILORIDE; CORTICOTROPIN; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; SODIUM; STEROID 11BETA MONOOXYGENASE;

ARTICLE; BRACHYDACTYLY; CARBOXY TERMINAL SEQUENCE; CHILD; ENDOCYTOSIS; ENZYME ACTIVITY; GENE MUTATION; GORDON SYNDROME; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LIDDLE SYNDROME; MOLECULAR GENETICS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; SODIUM ABSORPTION; SODIUM RETENTION;

EID: 0032459346     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(99)00007-7     Document Type: Article

References (72)

1. Siffert W, Rosskopf D, Siffert Get al. Association of a human G-protein β3 subunit variant with hypertension. Nat Genet. 18:1998;45-48.
2. Benjafield AV, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ G-protein β3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension. 32:1998;1094-1097.
3. Sutherland DJ, Ruse JL, Laidlaw JC Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 95:1966;1109-1119.
4. New MI, Peterson RE A new form of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 27:1967;300-305.
5. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med. 116:1992;813-820.
6. Lifton RP, Dluhy RG, Powers Met al. A chimeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 355:1992;262-265.
7. Lifton RP, Dluhy RG, Powers Met al. Hereditary hypertension caused by chimeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 2:1992;66-74.
8. Pascoe L, Curnow KM, Slutsker Let al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA. 89:1992;8327-8331.
9. Pascoe L, Jeunemaitre X, Lebrethon M-Cet al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest. 96:1995;2236-2246.
10. Curnow KM, Mulatero P, Emeric-Blanchouin N, Aupetit-Faisant B, Corvol P, Pascoe L The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYPB1, into an aldosterone producing enzyme. Nat Struct Biol. 4:1997;32-35.
11. Lifton RP, Dluhy RP. Inherited forms of mineralocorticoid hypertension: Glucocorticoid-remediable aldosteronism and the syndrome of apparent mineralocorticoid excess. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Press, 1995:2163-2175.
12. Carroll J, Dluhy R, Fallo Fet al. Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimerica gene duplication. J Clin Endocrinol Metab. 81:1996;4310-4312.
13. Lifton RP Genetic determinants of human hypertension. Proc Natl Acad Sci USA. 92:1995;8545-8551.
14. Pascoe L, Curnow KM Genetic recombination as a cause of inherited disorders of aldosterone and cortisol biosynthesis and a contributor to genetic variation in blood pressure. Steroids. 60:1995;22-27.
15. Dluhy RG, Williams GH Glucocorticoid-remediable aldosteronism. Cardiovasc Res. 31:1996;870-872.
16. White PC, Dupont J, New MI, Lieberman E, Hochberg Z, Rosler A A mutation in CYP11B1 (Arg4886→His) associated with steroid 11β-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest. 75:1991;1664-16676.
17. Helmberg A, Ausserer B, Kofler R Frame shift by insertion of 2 base pairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. J Clin Endocrinol Metab. 75:1992;1278-1281.
18. Curnow KM, Slutsker L, Vitek Jet al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci USA. 90:1993;4552-4556.
19. Ulick S, Levine LS, Gunczler Pet al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab. 49:1979;757-764.
20. Arriza JL, Weinberger C, Cerelli Get al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 237:1987;268-275.
21. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 105:1994;R11-R17.
22. Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet. 10:1995;394-399.
23. Stewart PM, Krozowski ZS, Gupta Aet al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet. 347:1996;88-91.
24. Ktanaka S, Katsumata N, Tanae Aet al. A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 82:1997;4054-4058.
25. Wilson RC, Krozowski ZS, Li Ket al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 80:1995;2263-2266.
26. Mune T, White PC Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension. 17:1996;1122-1128.
27. Krozlowski ZS, Stewart PM, Obeyesekere VR, Li K, Ferrari P Mutations in the 11β-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth. Clin Exp Hypertens. 19:1997;519-529.
28. Obeyesekere VR, Li KXZ, Ferrari P, Krozowski Z Truncation of the N- and C-terminal regions of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. Mol Cell Endocrinol. 131:1997;173-182.
29. Li A, Li KXZ, Marui Set al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens. 15:1997;1397-1402.
30. White PC, Mune T, Agarwal AK 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrinol Rev. 18:1997;135-156.
31. White PC Inherited forms of mineralocorticoid hypertension. Hypertension. 28:1996;927-936.
32. White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK Molecular analysis of 11β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Steroids. 62:1997;83-88.
33. Liddle GW, Bledsoe T, Coppage WS Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians. 76:1963;199-213.
34. Botero-Velez M, Curtis JJ, Warnock DG Liddle's syndrome revisited. A disorder of sodium reabsorption in the distal tubule. N Engl J Med. 330:1994;178-181.
35. Canessa CM, Horisberger J, Rossier BC Epithelial sodium channel related to proteins involved in neurodegeneration. Nature. 361:1993;467-470.
36. + channel. FEBS Lett. 318:1993;95-99.
37. + channel is made up of three homologous subunits. Nature. 349:1994;588-593.
38. Shimkets RA, Warnock DG, Bositis CMet al. Liddle's syndrome: Heritable hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell. 79:1994;407-414.
39. Schild L, Canessa CM, Shimkets RA, Gautschi I, Lifton RP, Rossier BC A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci USA. 92:1995;5699-5703.
40. Baker E, Jeunemaitre X, Portal AJet al. Abnormalities of nasal potential difference measurement in Liddle's syndrome. J Clin Invest. 102:1998;10-14.
41. Hansson JH, Schild L, Lu Yet al. A de novo missense mutation of the β-subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA. 92:1995;11495-11499.
42. Tamura H, Schild L, Enomoto N, Matsui N, Marumo F, Rossier BC Liddle disease caused by a missense mutation of β subunit of the epithelial sodium channel gene. J Clin Invest. 97:1996;1780-1784.
43. Findling JW, Raff H, Hansson JH, Lifton RP Liddle's syndrome: Prospective genetic screening and suppressed aldosterone secretion in an extended kindred. J Clin Endocrinol Metab. 82:1997;1071-1074.
44. Jeunemaitre X, Bassilana F, Persu Aet al. Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J Hypertens. 15:1997;1091-1100.
45. Hansson JH, Nelson-Williams C, Suzuki Het al. Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 11:1995;76-82.
46. Staub O, Dho S, Henry PCet al. WW domains of Nedd4 bind to the proline-rich PY motif in the epithelial sodium channel deleted in Liddle's syndrome. EMBO J. 15:1996;2371-2380.
47. Firsov D, Schild L, Gautschi I, Mérillat A-M, Schneeberger E, Rossier BC Cell surface expression of the epithelial Na channel and a mutant causing Liddle syndrome: A quantitative approach. Proc Natl Acad Sci USA. 93:1996;15370-15375.
48. Snyder P, Price M, McDonald Fet al. Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial sodium channel. Cell. 83:1995;969-978.
49. Kellenberger S, Gautschi I, Rossier BC, Schild L Mutations causing Liddle's syndrome reduce sodium-dependent downregulation of the epithelial sodium channel in the Xenopus oocyte expression system. J Clin Invest. 101:1998;2741-2750.
50. Rossier BC 1996 Homer Smith Award Lecture. Cum grano salis: The epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol. 8:1997;980-992.
51. Palmer BF, Alpern RJ Liddle's syndrome. Am J Med. 104:1998;301-309.
52. Paver WK, Pauline GJ Hypertension and hyperpotassiumemia without renal disease in a young male. Med J Aust. 2:1964;305-306.
53. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Aust Ann Med. 4:1970;287-294.
54. Schambelan M, Sebastian A, Rector FC Mineralocorticoid-resistant renal hyperkalaemia without salt wasting (type II pseudohypoaldosteronism): Role of increased renal chloride reabsorption. Kidney Int. 19:1981;716-727.
55. Mansfield TA, Simon DB, Farfel Z, Bia Met al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohyperaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet. 16:1997;202-205.
56. O'Shaughnessy KM, Fu B, Johnson AG, Gordon RD. Linkage of Gordon's Syndrome to chromosome 17 (abstr). High Blood Press Res Council Aust 19th Ann Sci Mtg 1997:1.
57. Jeunemaitre X, Soubrier F, Kotelevtsev YVet al. Molecular basis of human hypertension: Role of angiotensinogen. Cell. 71:1992;169-180.
58. Julier C, Delepine M, Keavney Bet al. Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum Mol Genet. 6:1997;2077-2086.
59. Mulligan LM, Kwok JB, Healey CSet al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363:1993;458-460.
60. Hofstra RM, Landsvater RM, Ceccherini Iet al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:1994;319-320.
61. Moley JF, Brother MB, Fong CTet al. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndrome. Cancer Res. 52:1992;770-774.
62. Latif F, Tory K, Gnarra Jet al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 260:1993;1317-1320.
63. Wallace MR, Collins FS Molecular genetics of von Reckinghausen neurofibrommatosis. Adv Hum Genet. 20:1991;267-307.
64. Schuster H, Wienker TF, Bähring Set al. Severe autosomal dominant hypertension and brachydactyly in a unique Turkish kindred maps to human chromosome 12. Nat Genet. 13:1996;98-100.
65. Bähring S, Nagai T, Toka HRet al. Deletion at 12p in a Japanese child with brachydactyly overlaps the assigned locus of brachydactyly with hypertension in a Turkish family. Am J Hum Genet. 60:1997;732-735.
66. Chitayat D, Grix A, Balfe JWet al. Brachydactyly short stature hypertension (Bilginturan) - report on two families. Am J Med Genet. 73:1997;279-285.
67. Schuster H, Wienker TF, Toka HRet al. Autosomal dominant hypertension and brachydactyly in a Turkish kindred resembles essential hypertension. Hypertension. 28:1996;1085-1092.
68. Naraghi R, Schuster H, Toka HRet al. Neurovascular compression at the ventrolateral medulla in autosomal dominant hypertension and brachdactyly. Stroke. 28:1997;1749-1754.
69. Simon DB, Karet FE, Hamdan JM, Di Pietro A, Sanjad SA, Lifton RP Bartter's syndrome, hypokalaemic alkylosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NNCC2. Nat Genet. 13:1996;183-188.
70. Takeuchi K, Kure S, Kato Tet al. Association of a mutation in thiazide-sensitive NaCl cotransporter with familial Gitelman's syndrome. J Clin Invest. 81:1996;4496-4499.
71. + channel ROMK. Nat Genet. 14:1996;152-156.
72. Simon DB, Bindra RS, Mansfield TAet al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome. Nat Genet. 17:1997;171-178.